Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended TARPEYO in Primary IgA Nephropathy
NCT06712407Phase 4Active, not recruiting
- Sponsor
- Calliditas Therapeutics AB
- Start
- Dec 2024
- Primary completion
- Mar 2027
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of EPI-EE in IgA nephropathy (IgAN), sponsored by Calliditas Therapeutics AB. Primary endpoint: Ratio of Urine Protein to Creatinine Ratio at 6 months. Started Dec 2024; status: active, not recruiting.
02
Drugs
EPI-EE
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT06712407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712407.